I must warn readers upfront that we at Seneca are value investors, and are thus naturally sceptical about growth investing in its simplest form, namely buying the stocks of companies that exhibit the highest sales, assets, profits, growth, etc.
However, we are equally sceptical about simplistic value investing, namely buying stocks just because they have low price-to-equity, price-to-book, price-to-sales ratios, etc. The original 'value investing'...
BB Biotech's Head of Investment, Daniel Koller, explains why the sector's fundamentals are all lined up to the upside.
Classes A and D remain unavailable
Has been sponsor since 2010
Hires RBC's Martin Heale
Bringing over two funds